| ¿µ¹® | bacteriocidal action | ÇÑ±Û | »ì±ÕÀÛ¿ë |
|---|---|---|---|
| ¼³¸í | ÈÇпä¹ýÁ¦, ¼Òµ¶Á¦ Áß¿¡´Â ¹Ì»ý¹°À» »ç¸ê½ÃŰ´Â ÀÛ¿ëÀÌ ÀÖ´Ù. À̰ÍÀ» »ì±ÕÀÛ¿ëÀ̶ó°í ÇÑ´Ù. ÀÌ¿¡ ´ëÇØ ¾î¶² ¾àÁ¦¿¡ ÀÇÇØ ±ÕÀÇ Áõ½ÄÀÌ ¾ïÁ¦°¡ µÇ´Âµ¥ ¾àÁ¦¸¦ Á¦°ÅÇÏ¸é ´Ù½Ã Áõ½ÄÇÏ´Â °ÍÀ» Á¤±ÕÀÛ¿ëÀ̶ó ÇÑ´Ù. |
||
| ¿µ¹® | buffer action | ÇÑ±Û | ¿ÏÃæÀÛ¿ë |
|---|---|---|---|
| ¼³¸í | Ç÷¾Ð, pH µî°ú °°ÀÌ »ýüÀÇ ±â´É ¹× »óŸ¦ ¾ÈÁ¤½Ã۰íÀÚ ÇÏ´Â ÀÛ¿ë : pH 7ÀÎ ¼ø¼öÇÑ ¹°¿¡¼ ¼Ò·®ÀÇ »ê ¶Ç´Â ¾ËÄ®¸®¸¦ °¡ÇÏ¸é ±× ¾ç¿¡ µû¶ó ¹°ÀÇ pH°¡ ¶Ñ·ÇÇÏ°Ô º¯ÇÑ´Ù. ±×·¯³ª ¾àÇÑ »ê°ú ±× ¿°ÀÇ È¥ÇÕ¿ë¾×, ¶Ç´Â ¾àÇÑ »ê±â¿Í ±× ¿°ÀÇ È¥ÇÕ¿ë¾×À¸·Î ÀÌ·ç¾îÁö´Â °è¿¡¼´Â ¾à°£ÀÇ »ê ¶Ç´Â ¾ËÄ®¸®¸¦ °¡Çصµ ¿ÏÃæÀÛ¿ë ¶§¹®¿¡ pH´Â °ÅÀÇ º¯ÇÏÁö ¾Ê´Â´Ù. ¿¹¸¦ µé¾î, ¾àÇÑ »ê°ú ±× ¿°ÀÇ È¥ÇÕ¿ë¾×À¸·Î ÀÌ·ç¾îÁö´Â °èͧ¿¡ »êÀ» °¡ÇßÀ» ¶§¸¦ »ý°¢Çϸé, »ê¿¡ ÀÇÇØ¼ °¡ÇØÁø ¼ö¼ÒÀ̿ H+Àº ¾àÇÑ »êÀ̿°ú °áÇÕÇÏ¿© ºñÇØ¸®ÀÎ »êÀÌ µÇ¾î pH°¡ º¯ÇÏÁö ¾Ê´Â´Ù. ¶Ç ¾ËÄ®¸®¸¦ °¡ÇßÀ» ¶§´Â °¡ÇØÁø ¼ö»êÀ̿ OH£ÀÌ H+°ú °áÇÕÇÏ¿© ¹°À» ¸¸µé°í, ºÎÁ·ÇÑ H+Àº ºñÇØ¸® ¾àÇÑ »êÀÇ ÇØ¸®¿¡ ÀÇÇØ¼ º¸ÃæµÇ¹Ç·Î½á ¿ª½Ã pH´Â º¯ÇÏÁö ¾Ê´Â´Ù. |
||
| ¿µ¹® | bacteriostatic action | ÇÑ±Û | Á¤±ÕÀÛ¿ë |
|---|---|---|---|
| ¼³¸í | ÈÇпä¹ýÁ¦ÀÇ ¼¼±Õ¿¡ ´ëÇÑ ÀÛ¿ë Áß¿¡¼ ¾î¶² ¾àÁ¦¸¦ ¼¼±Õ¿¡ ÀÛ¿ë½Ã۸é, ±ÕÀÇ Áõ½ÄÀº ¾ïÁ¦µÇ³ª ±× ¾àÁ¦°¡ Á¦°ÅµÇ¸é ÀçÂ÷ Áõ½ÄÇÑ´Ù. ÀÌ¿Í °°Àº ÀÛ¿ëÀ» Á¤±ÕÀÛ¿ëÀ̶ó°í ÇÑ´Ù. ¿¹·Î¼ Ŭ·Î¶÷Æä´ÏÄÝ, ¼³ÆÄ¹Î µîÀÌ ÀÖ´Ù. |
||
| AHF | acute heart failure; American Health Foundation; American Hepatic Foundation; American Hospital Form... |
|---|---|
| NPF | nasopharyngeal fiberscope; National Parkinson Foundation; National Pharmaceutical Foundation; Nation... |
| MAP | malignant atrophic papulosis; mandibular angle plane; maturation-activated protein; maximal aerobic ... |
| ADC | AIDS Dementia Complex; AIDS Ä¡¸Å º¹ÇÕ |
| ARC | AIDS Related Complex; AIDS °ü·Ã º¹ÇÕ |
| AIDS-KS | AIDS- related Kaposi's sarcoma |
|---|---|
| AIDS-KS | AIDS-associated Kaposi sarcoma |
| AIDS-NHL | AIDS-related non-Hodgkin lymphomas |
| CCF | Cleveland Clinic Foundation |
| JDF | Juvenile Diabetes Foundation |
| mean foundation plane | The mean of the various irregularities in form and inclination of the basal seat; the ideal condition for denture stability exists when the mean foundation plane is most nearly at right angles to the direction of force. (05 Mar 2000) |
|---|---|
| National Science Foundation | <organisation> A nonregulatory U.S. Federal agency which has oversight of biotechnology research activities that the agency funds. (09 Oct 1997) |
| denture foundation | That portion of the oral structures which is available to support a denture. See: denture foundation area, denture foundation surface, mean foundation plane. (05 Mar 2000) |
| denture foundation area | That portion of the basal seat which supports the complete or partial denture base under occlusal load. Synonym: basal seat, denture-bearing area, denture-supporting area, stress-bearing area, supporting area, tissue-bearing area. (05 Mar 2000) |
| denture foundation surface | That portion of the surface of a denture which has its contour determined by the impression and bears the greater part of the occlusal load. Synonym: denture basal surface. (05 Mar 2000) |
| foundation | A base; a supporting structure. (05 Mar 2000) |
| AIDS | <immunology, syndrome> An epidemic disease caused by an infection by human immunodeficiency virus (HIV-1, HIV-2), a retrovirus that causes immune system failure and debilitation and is often accompanied by infections such as tuberculosis. AIDS is spread through direct contact with bodily fluids. Acronym: AIDS (10 May 1997) |
| aids-associated nephropathy | Renal syndrome in human immunodeficiency virus-infected patients characterised by nephrotic syndrome, severe proteinuria, focal and segmental glomerulosclerosis with distinctive tubular and interstitial changes, enlarged kidneys, and peculiar tubuloreticular structures. The syndrome is distinct from heroin-associated nephropathy as well as other forms of kidney disease seen in HIV-infected patients. (12 Dec 1998) |
| AIDS-defining illness | <immunology> One of a list of serious illnesses that occurs in HIV-positive individuals and is reason for an AIDS diagnosis according to the CDC's definition of AIDS. Among these conditions are PCP, MAC, AIDS dementia complex, AIDS wasting syndrome, invasive cervical cancer, Kaposi's sarcoma and CMV retinitis. (09 Oct 1997) |
| AIDS dementia | <immunology> A frequent cerebral condition in people with AIDS that results in the loss of cognitive capacity, affecting the ability to function in a social or occupational setting. Its cause has not been determined exactly, but may result from HIV infection of cells in the brain or an inflammatory reaction to such infection. (09 Oct 1997) |
| AIDS dementia complex | <immunology> A frequent cerebral condition in people with AIDS that results in the loss of cognitive capacity, affecting the ability to function in a social or occupational setting. Its cause has not been determined exactly, but may result from HIV infection of cells in the brain or an inflammatory reaction to such infection. (09 Oct 1997) |
| aids-related complex | A prodromal phase of infection with the human immunodeficiency virus (HIV). Laboratory criteria separating aids-related complex (arc) from aids include elevated or hyperactive B-cell humoral immune responses, compared to depressed or normal antibody reactivity in aids; follicular or mixed hyperplasia in arc lymph nodes, leading to lymphocyte degeneration and depletion more typical of aids; evolving succession of histopathological lesions such as localization of kaposi's sarcoma, signaling the transition to the full-blown aids. (12 Dec 1998) |
| aids-related opportunistic infections | Opportunistic infections found in patients who test positive for human immunodeficiency virus (HIV). The most common include pneumocystis carinii pneumonia, kaposi's sarcoma, cryptosporidiosis, herpes simplex, toxoplasmosis, cryptococcosis, and infections with mycobacterium avium complex, microsporidium, and cytomegalovirus. (12 Dec 1998) |
| AIDS-related virus | An obsolete term for human immunodeficiency virus. (05 Mar 2000) |
| aids serodiagnosis | Immunologic tests for identification of HIV (HTLV-III/lav) antibodies. They include assays for HIV seropositivity and HIV seronegativity (elisa, immunofluorescence, immunoblot, etc.) that have been developed for screening persons carrying the viral antibody from patients with overt symptoms of aids or aids-related complex. (12 Dec 1998) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|